GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Varian Medical Systems Inc (NYSE:VAR) » Definitions » Cash, Cash Equivalents, Marketable Securities

Varian Medical Systems (Varian Medical Systems) Cash, Cash Equivalents, Marketable Securities : $773 Mil (As of Dec. 2020)


View and export this data going back to 1976. Start your Free Trial

What is Varian Medical Systems Cash, Cash Equivalents, Marketable Securities?

Varian Medical Systems's quarterly cash, cash equivalents, marketable securities declined from Jun. 2020 ($769.20 Mil) to Sep. 2020 ($766.10 Mil) but then increased from Sep. 2020 ($766.10 Mil) to Dec. 2020 ($773.30 Mil).

Varian Medical Systems's annual cash, cash equivalents, marketable securities increased from Sep. 2018 ($504.80 Mil) to Sep. 2019 ($531.40 Mil) and increased from Sep. 2019 ($531.40 Mil) to Sep. 2020 ($766.10 Mil).


Varian Medical Systems Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Varian Medical Systems's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Varian Medical Systems Cash, Cash Equivalents, Marketable Securities Chart

Varian Medical Systems Annual Data
Trend Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 906.70 716.20 504.80 531.40 766.10

Varian Medical Systems Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 721.90 667.80 769.20 766.10 773.30

Varian Medical Systems Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Varian Medical Systems  (NYSE:VAR) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Varian Medical Systems Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Varian Medical Systems's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Varian Medical Systems (Varian Medical Systems) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3100 Hansen Way, Palo Alto, CA, USA, 94304-1038
Varian Medical Systems designs, manufactures, and sells radiation technology for use in two business segments: oncology systems and proton therapy. The Americas account for the largest portion of revenue (47%), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (19%).
Executives
Jesse Michael Bruff officer: SVP Finance, CFO 3100 HANSEN WAY, PALO ALTO CA 94304
Magnus Momsen officer: SVP, CAO, Corporate Controller VARIAN MEDICAL SYSTEMS INC. 3100 HANSEN WAY MAIL STOP E327 PALO ALTO CA 94304
Dow R Wilson director, officer: President and CEO VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Kolleen T Kennedy officer: Pres. Proton Solutions, CGO VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Christopher A. Toth officer: SVP and Pres. Oncology Systems 1252 COOLIDGE AVE., SAN JOSE CA 95125
Michael Damon Hutchinson officer: SVP,Chief Legal Officer, Secy 2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Jean Luc Butel director ONE BAXTER PARKWAY, DEERFIELD IL 60015
John W Kuo officer: SVP, Gen Counsel and Secretary VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Judy Bruner director C/O SANDISK CORPORATION, 601 MCCARTHY BLVD., MILPITAS CA 95035
Beau Michelle Le director 800 N. MICHIGAN AVENUE #3703 CHICAGO IL 60611
Anat Ashkenazi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jeffrey R. Balser director 3657 RICHLAND AVE., NASHVILLE TN 37205
Regina E Dugan director VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
David J Illingworth director 3100 HANSEN WAY PALO ALTO CA 94304
R Andrew Eckert director THREE RAVINIA DRIVE, ATLANTA GA 30346

Varian Medical Systems (Varian Medical Systems) Headlines

From GuruFocus

Varian Announces CEO Succession Plan

By PRNewswire PRNewswire 03-02-2021